Replimune Group Inc (REPL): Next-Year EPS Estimate 46.76%
As of 2026-05-20, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 46.76%. Featured in our EPS revision report on 2026-04-22.
On 2026-05-19, analyst consensus for REPL's next-year EPS growth shifted from 46.40% to 46.76% — a positive change of 0.36 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 0.28%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 46.76%
- EPS growth this year
- 0.28%
- EPS next quarter (est)
- -$0.66
- Last price
- $5.16
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-20 | 46.76% | 0.28% | -$0.66 | $5.16 |
| 2026-05-19 | 46.76% | 0.28% | -$0.66 | $4.70 |
| 2026-05-18 | 46.40% | 0.77% | -$0.65 | $5.01 |
| 2026-05-17 | 46.40% | 0.77% | -$0.65 | $5.22 |
| 2026-05-14 | 46.40% | 0.77% | -$0.65 | $4.93 |
| 2026-05-13 | 46.40% | 0.77% | -$0.65 | $5.38 |
| 2026-05-12 | 46.40% | 0.77% | -$0.65 | $4.09 |
| 2026-05-11 | 46.40% | 0.77% | -$0.65 | $3.74 |
| 2026-05-10 | 46.40% | 0.77% | -$0.65 | $4.07 |
| 2026-05-07 | 46.40% | 0.77% | -$0.65 | $3.34 |
| 2026-05-06 | 46.40% | 0.77% | -$0.65 | $3.44 |
| 2026-05-05 | 46.40% | 0.77% | -$0.65 | $2.87 |
| 2026-05-04 | 46.40% | 0.77% | -$0.65 | $3.03 |
| 2026-05-03 | 46.40% | 0.77% | -$0.65 | $2.50 |
| 2026-04-30 | 46.40% | 0.77% | -$0.65 | $2.57 |
| 2026-04-29 | 46.40% | 0.77% | -$0.65 | $2.38 |
| 2026-04-28 | 46.40% | 0.77% | -$0.65 | $2.57 |
| 2026-04-27 | 46.40% | 0.77% | -$0.65 | $2.68 |
| 2026-04-26 | 46.40% | 0.77% | -$0.65 | $2.42 |
| 2026-04-24 | 46.40% | 0.77% | -$0.65 | $2.42 |
| 2026-04-23 | 46.40% | 0.77% | -$0.65 | $2.85 |
| 2026-04-22 | 46.40% | 0.77% | -$0.65 | $2.27 |
| 2026-04-21 | 46.40% | 0.77% | -$0.65 | $1.86 |
| 2026-04-20 | 46.40% | 0.77% | -$0.65 | $2.07 |
| 2026-04-19 | 46.40% | 0.77% | -$0.65 | $2.17 |
| 2026-04-16 | 46.40% | 0.77% | -$0.65 | $2.19 |
| 2026-04-15 | 46.40% | 0.77% | -$0.65 | $2.28 |
| 2026-04-14 | 46.40% | 0.77% | -$0.65 | $1.95 |
| 2026-04-13 | 46.40% | 0.77% | -$0.65 | $1.70 |
| 2026-04-12 | 34.42% | -1.33% | -$0.69 | $4.76 |
Reports Featuring REPL
Recent News
- Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.Barrons.com
- Replimune melanoma therapy rejected by FDA, shares plungeProactive
- FDA issues complete response letter to Replimunes RP1 for melanomaPharmaceutical Technology
- Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgradedInvesting.com
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
Screen Performance
Aggregate stats across all 1713 tickers our top-EPS-revision screen has flagged over the past 49 days.
- Median return since detection
- +2.8%
- % of tickers in the green
- 58%
- Median return on winners
- +15.1%
- Large revisions captured
- 630
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Replimune Group Inc's next-year EPS growth estimate?▾
As of 2026-05-20, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 46.76%, based on analyst consensus.
When was the latest EPS estimate revision for REPL?▾
The most recent revision occurred on 2026-05-19, when analysts adjusted the next-year EPS growth estimate from 46.40% to 46.76%.
What sector and industry does Replimune Group Inc belong to?▾
Replimune Group Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. REPL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Replimune Group Inc (REPL) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports